A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome - Related Studies

A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome

This study has been completed.

Study NCT00000737. Last updated on August 22, 2008. Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cachexia
		HIV Infections
		HIV Wasting Syndrome

2	Additional conditions recognized in this trial
		Acquired Immunodeficiency Syndrome
		Infection
		Syndrome
		Wasting Syndrome

3	More general conditions related to this trial
		Body Weight
		Body Weight Changes
		Disease
		Emaciation
		Immune System Diseases
		Immunologic Deficiency Syndromes
		Lentivirus Infections
		Metabolic Diseases
		Nutrition Disorders
		Pathologic Processes
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Signs and Symptoms
		Slow Virus Diseases
		Virus Diseases
		Weight Loss

4	Interventions listed in this trial
		Dronabinol
		Megestrol acetate

5	Additional drug interventions recognized in this trial
		Megestrol
		Tetrahydrocannabinol

6	More general drug interventions related to this trial
		Analgesics
		Analgesics, Non-Narcotic
		Antineoplastic Agents
		Antineoplastic Agents, Hormonal
		Appetite Stimulants
		Central Nervous System Agents
		Central Nervous System Stimulants
		Contraceptive Agents
		Contraceptive Agents, Female
		Contraceptives, Oral
		Contraceptives, Oral, Synthetic
		Hallucinogens
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Psychotropic Drugs
		Reproductive Control Agents
		Sensory System Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		National Institute of Allergy and Infectious Diseases (NIAID)
		Roxane Laboratories
		Bristol-Myers Squibb